Functional evidence that α2A-adrenoceptors are responsible for antilipolysis in human abdominal fat cells

Gábor Tarkovács, Corrado Blandizzi, E. Vízi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The effects of α2-adrenoceptor agonists (dexmedetomidine, oxymetazoline), alone or in combination with various α-adrenoceptor subtype-selective antagonists (CH-38083, idazoxan, WB4101, BRL44408, ARC-239, prazosin), on noradrenaline- and isoprenaline-induced lipolysis were investigated in human isolated abdominal subcutaneous fat cells. The rank order of potency of antagonists in preventing dexmedetomidine- and oxymetazoline-evoked suppression of isoprenaline-induced lipolysis was (pA2-values): CH-38083 (7.69 and 7.48) ≅ idazoxan (7.5 and 7.41) > BRL 44408 (7.23 and 7.19) ≅ WB 4101 (7.13 and 7.12) > prazosin (5.18 and 5.17) > ARC-239 (4.72, 4.9). While CH-38083 and idazoxan, non-subtype selective α2-adrenoceptor antagonists and BRL44408, a selective a2A-adrenoceptor antagonist as well as WB4101 potentiated the lipolytic effect of noradrenaline, ARC-239, the selective α2B-adrenoceptor antagonist failed to affect it. In addition since the α2A-adrenoceptor selective agonist, oxymetazoline concentration dependently inhibited the lipolytic effect of isoprenaline, and WB4101 and BRL44408 (a2A-adrenoceptor antagonists) antagonised the effect of oxymetazoline in a competitive manner, it is concluded that the a2A-adrenoceptor subtype is involved in antilipolysis. In addition, functional evidence was obtained that there is an interaction between α2A- and β-adrenoceptors located on the cell surface of adipocytes, through which locally released noradrenaline and/or circulating circulating adrenaline influence lipolysis.

Original languageEnglish
Pages (from-to)34-41
Number of pages8
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume349
Issue number1
DOIs
Publication statusPublished - Jan 1994

Fingerprint

Abdominal Fat
Adipocytes
Adrenergic Receptors
Oxymetazoline
Idazoxan
Lipolysis
Isoproterenol
Dexmedetomidine
Norepinephrine
Prazosin
Abdominal Subcutaneous Fat
Epinephrine
(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane

Keywords

  • α-adrenoceptors
  • β-adrenoceptors
  • Human fat cell
  • Interplay of α-
  • Lipolysis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Functional evidence that α2A-adrenoceptors are responsible for antilipolysis in human abdominal fat cells. / Tarkovács, Gábor; Blandizzi, Corrado; Vízi, E.

In: Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 349, No. 1, 01.1994, p. 34-41.

Research output: Contribution to journalArticle

@article{bf5d9dca417b45629778aea8c2fd4d37,
title = "Functional evidence that α2A-adrenoceptors are responsible for antilipolysis in human abdominal fat cells",
abstract = "The effects of α2-adrenoceptor agonists (dexmedetomidine, oxymetazoline), alone or in combination with various α-adrenoceptor subtype-selective antagonists (CH-38083, idazoxan, WB4101, BRL44408, ARC-239, prazosin), on noradrenaline- and isoprenaline-induced lipolysis were investigated in human isolated abdominal subcutaneous fat cells. The rank order of potency of antagonists in preventing dexmedetomidine- and oxymetazoline-evoked suppression of isoprenaline-induced lipolysis was (pA2-values): CH-38083 (7.69 and 7.48) ≅ idazoxan (7.5 and 7.41) > BRL 44408 (7.23 and 7.19) ≅ WB 4101 (7.13 and 7.12) > prazosin (5.18 and 5.17) > ARC-239 (4.72, 4.9). While CH-38083 and idazoxan, non-subtype selective α2-adrenoceptor antagonists and BRL44408, a selective a2A-adrenoceptor antagonist as well as WB4101 potentiated the lipolytic effect of noradrenaline, ARC-239, the selective α2B-adrenoceptor antagonist failed to affect it. In addition since the α2A-adrenoceptor selective agonist, oxymetazoline concentration dependently inhibited the lipolytic effect of isoprenaline, and WB4101 and BRL44408 (a2A-adrenoceptor antagonists) antagonised the effect of oxymetazoline in a competitive manner, it is concluded that the a2A-adrenoceptor subtype is involved in antilipolysis. In addition, functional evidence was obtained that there is an interaction between α2A- and β-adrenoceptors located on the cell surface of adipocytes, through which locally released noradrenaline and/or circulating circulating adrenaline influence lipolysis.",
keywords = "α-adrenoceptors, β-adrenoceptors, Human fat cell, Interplay of α-, Lipolysis",
author = "G{\'a}bor Tarkov{\'a}cs and Corrado Blandizzi and E. V{\'i}zi",
year = "1994",
month = "1",
doi = "10.1007/BF00178203",
language = "English",
volume = "349",
pages = "34--41",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Functional evidence that α2A-adrenoceptors are responsible for antilipolysis in human abdominal fat cells

AU - Tarkovács, Gábor

AU - Blandizzi, Corrado

AU - Vízi, E.

PY - 1994/1

Y1 - 1994/1

N2 - The effects of α2-adrenoceptor agonists (dexmedetomidine, oxymetazoline), alone or in combination with various α-adrenoceptor subtype-selective antagonists (CH-38083, idazoxan, WB4101, BRL44408, ARC-239, prazosin), on noradrenaline- and isoprenaline-induced lipolysis were investigated in human isolated abdominal subcutaneous fat cells. The rank order of potency of antagonists in preventing dexmedetomidine- and oxymetazoline-evoked suppression of isoprenaline-induced lipolysis was (pA2-values): CH-38083 (7.69 and 7.48) ≅ idazoxan (7.5 and 7.41) > BRL 44408 (7.23 and 7.19) ≅ WB 4101 (7.13 and 7.12) > prazosin (5.18 and 5.17) > ARC-239 (4.72, 4.9). While CH-38083 and idazoxan, non-subtype selective α2-adrenoceptor antagonists and BRL44408, a selective a2A-adrenoceptor antagonist as well as WB4101 potentiated the lipolytic effect of noradrenaline, ARC-239, the selective α2B-adrenoceptor antagonist failed to affect it. In addition since the α2A-adrenoceptor selective agonist, oxymetazoline concentration dependently inhibited the lipolytic effect of isoprenaline, and WB4101 and BRL44408 (a2A-adrenoceptor antagonists) antagonised the effect of oxymetazoline in a competitive manner, it is concluded that the a2A-adrenoceptor subtype is involved in antilipolysis. In addition, functional evidence was obtained that there is an interaction between α2A- and β-adrenoceptors located on the cell surface of adipocytes, through which locally released noradrenaline and/or circulating circulating adrenaline influence lipolysis.

AB - The effects of α2-adrenoceptor agonists (dexmedetomidine, oxymetazoline), alone or in combination with various α-adrenoceptor subtype-selective antagonists (CH-38083, idazoxan, WB4101, BRL44408, ARC-239, prazosin), on noradrenaline- and isoprenaline-induced lipolysis were investigated in human isolated abdominal subcutaneous fat cells. The rank order of potency of antagonists in preventing dexmedetomidine- and oxymetazoline-evoked suppression of isoprenaline-induced lipolysis was (pA2-values): CH-38083 (7.69 and 7.48) ≅ idazoxan (7.5 and 7.41) > BRL 44408 (7.23 and 7.19) ≅ WB 4101 (7.13 and 7.12) > prazosin (5.18 and 5.17) > ARC-239 (4.72, 4.9). While CH-38083 and idazoxan, non-subtype selective α2-adrenoceptor antagonists and BRL44408, a selective a2A-adrenoceptor antagonist as well as WB4101 potentiated the lipolytic effect of noradrenaline, ARC-239, the selective α2B-adrenoceptor antagonist failed to affect it. In addition since the α2A-adrenoceptor selective agonist, oxymetazoline concentration dependently inhibited the lipolytic effect of isoprenaline, and WB4101 and BRL44408 (a2A-adrenoceptor antagonists) antagonised the effect of oxymetazoline in a competitive manner, it is concluded that the a2A-adrenoceptor subtype is involved in antilipolysis. In addition, functional evidence was obtained that there is an interaction between α2A- and β-adrenoceptors located on the cell surface of adipocytes, through which locally released noradrenaline and/or circulating circulating adrenaline influence lipolysis.

KW - α-adrenoceptors

KW - β-adrenoceptors

KW - Human fat cell

KW - Interplay of α-

KW - Lipolysis

UR - http://www.scopus.com/inward/record.url?scp=0028177928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028177928&partnerID=8YFLogxK

U2 - 10.1007/BF00178203

DO - 10.1007/BF00178203

M3 - Article

VL - 349

SP - 34

EP - 41

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 1

ER -